Literature DB >> 30744961

Universal regimens or universal access to drug susceptibility testing for tuberculosis?

Rebecca Acquah1, Jennifer Furin2.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 30744961     DOI: 10.1016/S1473-3099(18)30742-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  3 in total

1.  Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

Authors:  Francesca Conradie; Tatevik R Bagdasaryan; Sergey Borisov; Pauline Howell; Lali Mikiashvili; Nosipho Ngubane; Anastasia Samoilova; Sergey Skornykova; Elena Tudor; Ebrahim Variava; Petr Yablonskiy; Daniel Everitt; Genevieve H Wills; Eugene Sun; Morounfolu Olugbosi; Erica Egizi; Mengchun Li; Alda Holsta; Juliano Timm; Anna Bateson; Angela M Crook; Stella M Fabiane; Robert Hunt; Timothy D McHugh; Conor D Tweed; Salah Foraida; Carl M Mendel; Melvin Spigelman
Journal:  N Engl J Med       Date:  2022-09-01       Impact factor: 176.079

Review 2.  Quality of drug-resistant tuberculosis care: Gaps and solutions.

Authors:  Zarir Udwadia; Jennifer Furin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-04-24

3.  Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial.

Authors:  Annelies Van Rie; Elise De Vos; Emilyn Costa; Lennert Verboven; Felex Ndebele; Tim H Heupink; Steven Abrams; Boitumelo Fanampe; Anneke Van der Spoel Van Dyk; Salome Charalambous; Gavin Churchyard; Rob Warren
Journal:  Trials       Date:  2022-10-08       Impact factor: 2.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.